A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

PURPOSE: Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. PATIENTS AND METHODS: Aphase 2, randomized, placebo‐controlled, multicenter trial evaluated the activity of tarextu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zishuo Ian, Bendell, Johanna C., Bullock, Andrea, LoConte, Noelle K., Hatoum, Hassan, Ritch, Paul, Hool, Hugo, Leach, Joseph W., Sanchez, James, Sohal, Davendra P. S., Strickler, John, Patel, Ravindranath, Wang‐Gillam, Andrea, Firdaus, Irfan, Yu, Kenneth H., Kapoun, Ann M., Holmgren, Eric, Zhou, Lei, Dupont, Jakob, Picozzi, Vincent, Sahai, Vaibhav, O'Reilly, Eileen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718621/
https://www.ncbi.nlm.nih.gov/pubmed/31347292
http://dx.doi.org/10.1002/cam4.2425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718621/
https://www.ncbi.nlm.nih.gov/pubmed/31347292
http://dx.doi.org/10.1002/cam4.2425

Ejemplares similares